Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Engineers Gate Manager LP

Engineers Gate Manager LP lowered its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) by 63.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,957 shares of the biopharmaceutical company’s stock after selling 3,467 shares during the quarter. Engineers Gate Manager LP’s holdings in Alnylam Pharmaceuticals were worth $392,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in ALNY. Raymond James Financial Services Advisors Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 9.4% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 11,850 shares of the biopharmaceutical company’s stock valued at $1,935,000 after purchasing an additional 1,017 shares during the last quarter. MetLife Investment Management LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the first quarter valued at approximately $1,268,000. Panagora Asset Management Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 96.4% in the first quarter. Panagora Asset Management Inc. now owns 6,565 shares of the biopharmaceutical company’s stock valued at $1,072,000 after purchasing an additional 3,223 shares during the last quarter. Great West Life Assurance Co. Can increased its holdings in shares of Alnylam Pharmaceuticals by 21.2% in the first quarter. Great West Life Assurance Co. Can now owns 62,369 shares of the biopharmaceutical company’s stock valued at $10,786,000 after purchasing an additional 10,892 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Alnylam Pharmaceuticals by 1.2% in the first quarter. Dimensional Fund Advisors LP now owns 181,271 shares of the biopharmaceutical company’s stock valued at $29,601,000 after purchasing an additional 2,111 shares during the last quarter.

Alnylam Pharmaceuticals Trading Up 1.2 %

NASDAQ:ALNY opened at $184.86 on Tuesday. The firm has a market cap of $22.95 billion, a PE ratio of -19.90 and a beta of 0.49. The stock has a fifty day moving average price of $217.54 and a 200 day moving average price of $214.08. Alnylam Pharmaceuticals, Inc. has a 12-month low of $117.58 and a 12-month high of $242.97. The company has a current ratio of 3.51, a quick ratio of 3.34 and a debt-to-equity ratio of 3.85.

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) last released its earnings results on Thursday, February 23rd. The biopharmaceutical company reported ($1.68) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.13) by $0.45. The firm had revenue of $335.04 million during the quarter, compared to analyst estimates of $312.45 million. Alnylam Pharmaceuticals had a negative return on equity of 1,287.80% and a negative net margin of 109.04%. Alnylam Pharmaceuticals’s revenue was up 29.6% compared to the same quarter last year. During the same period last year, the business posted ($2.16) earnings per share. Sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, EVP Indrani Lall Franchini sold 1,675 shares of Alnylam Pharmaceuticals stock in a transaction dated Thursday, February 2nd. The stock was sold at an average price of $226.01, for a total transaction of $378,566.75. Following the completion of the sale, the executive vice president now directly owns 3,500 shares of the company’s stock, valued at approximately $791,035. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Alnylam Pharmaceuticals news, CMO Pushkal Garg sold 18,072 shares of Alnylam Pharmaceuticals stock in a transaction dated Friday, March 3rd. The stock was sold at an average price of $200.00, for a total transaction of $3,614,400.00. Following the completion of the sale, the chief marketing officer now directly owns 4,345 shares of the company’s stock, valued at approximately $869,000. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Indrani Lall Franchini sold 1,675 shares of Alnylam Pharmaceuticals stock in a transaction dated Thursday, February 2nd. The stock was sold at an average price of $226.01, for a total value of $378,566.75. Following the sale, the executive vice president now directly owns 3,500 shares of the company’s stock, valued at $791,035. The disclosure for this sale can be found here. 1.40% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Chardan Capital reaffirmed a “buy” rating and issued a $250.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, February 24th. JPMorgan Chase & Co. cut their target price on Alnylam Pharmaceuticals from $200.00 to $196.00 and set a “neutral” rating for the company in a research note on Friday, March 3rd. Needham & Company LLC reissued a “buy” rating and set a $240.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, February 24th. EF Hutton Acquisition Co. I initiated coverage on Alnylam Pharmaceuticals in a research note on Tuesday, February 21st. They set a “buy” rating and a $304.00 target price for the company. Finally, HC Wainwright reissued a “buy” rating and set a $415.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, March 3rd. Seven equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $244.26.

About Alnylam Pharmaceuticals

(Get Rating)

Alnylam Pharmaceuticals, Inc is a global commercial-stage biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. Its products include ONPATTRO, GIVLAARI, and OXLUMO. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R.